title: Viral vectors as vaccine platforms: deployment in sight.
abstract: A little more than a decade after the explosion of research into recombinant live-attenuated or replication-deficient viruses as vaccine platforms, many viral vector-based vaccines have been licensed for animals. Progress has been slower for humans but 2011 will see the licensure of the first viral-vectored vaccine for humans, against Japanese Encephalitis. In addition a vaccine with a viral-vectored component showed efficacy against HIV infection in humans. Viral-based vaccines have an excellent safety profile but must deal with the potential problem of pre-existing anti-vector immunity. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and better prime-boost approaches, suggesting that many viral vectors are approaching their final years as vaccine 'candidates' rather than vaccines.
authors.affiliation: Oxford Vaccine Group, Department of Paediatrics, Center for Clinical Vaccine and Tropical Medicine, University of Oxford, Churchill Hospital, Churchill Drive, Oxford OX3 7LJ, United Kingdom. Christine.rollier@paediatrics.ox.ac.uk
authors.forename: Christine S
authors.initials: CS
authors.lastname: Rollier
authors.forename: Arturo
authors.initials: A
authors.lastname: Reyes-Sandoval
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Cottingham
authors.forename: Katie
authors.initials: K
authors.lastname: Ewer
authors.forename: Adrian V S
authors.initials: AV
authors.lastname: Hill
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D016896:Treatment Outcome; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control*
chemical_list: D014765:Viral Vaccines